Ethyl 4-(trifluoromethylsulfonyloxy)-5,6,7,8-tetrahydronaphthalene-2-carboxylate | 1012069-66-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: Ethyl 4-(trifluoromethylsulfonyloxy)-5,6,7,8-tetrahydronaphthalene-2-carboxylate
• CAS: 1012069-66-7
• 化学式: C₁₄H₁₅F₃O₅S
• 分子量: 352.331
• InChiKey: QTJVJEMNFZFWTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  78
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Ethyl 4-(trifluoromethylsulfonyloxy)-5,6,7,8-tetrahydronaphthalene-2-carboxylate 在 bis-triphenylphosphine-palladium(II) chloride 、 sodium hydroxide 、 sodium tetrahydroborate 、 9-borabicyclo[3.3.1]nonane dimer 、 四溴化碳 、 sodium hydride 、 三苯基膦 、 sodium iodide 、 lithium chloride 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 3-<2-(3-carboxy-5,6,7,8-tetrahydronaphthyl)ethyl>coformycin aglycon
  参考文献：
  名称：

  AMP Deaminase Inhibitors. 5. Design, Synthesis, and SAR of a Highly Potent Inhibitor Series

  摘要：

  A highly potent AMP deaminase (AMPDA) inhibitor series was discovered by replacing the N3 substitutents of the two lead AMPDA inhibitor series with a conformationally restricted group. The most potent compound, 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydroaphthyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (24b), represents a 10- to 250-fold enhancement in AMPDA inhibitory potency without loss in the enzyme specificity. The potency of the inhibitor 24b (AMPDA K-i = 0.002 muM) is 10(5)-fold lower than the K-m for the substrate AMP. It represents the most potent nonnucleotide AMPDA inhibitor known.

  DOI：

  10.1021/jm000355t
• 作为产物：
  描述：

  2-氧代-5,6,7,8-四氢-2H-色满-3-羧酸乙酯 在 吡啶 作用下， 以 甲苯 为溶剂， 生成 Ethyl 4-(trifluoromethylsulfonyloxy)-5,6,7,8-tetrahydronaphthalene-2-carboxylate
  参考文献：
  名称：

  AMP Deaminase Inhibitors. 5. Design, Synthesis, and SAR of a Highly Potent Inhibitor Series

  摘要：

  A highly potent AMP deaminase (AMPDA) inhibitor series was discovered by replacing the N3 substitutents of the two lead AMPDA inhibitor series with a conformationally restricted group. The most potent compound, 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydroaphthyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (24b), represents a 10- to 250-fold enhancement in AMPDA inhibitory potency without loss in the enzyme specificity. The potency of the inhibitor 24b (AMPDA K-i = 0.002 muM) is 10(5)-fold lower than the K-m for the substrate AMP. It represents the most potent nonnucleotide AMPDA inhibitor known.

  DOI：

  10.1021/jm000355t

文献信息

• Benzo-fused compounds for use in treating metabolic disorders
  申请人：Brown Sean P.

  公开号：US20080119511A1

  公开（公告）日：2008-05-22

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，可用于治疗受试者的代谢紊乱等疾病。这些化合物的一般式为I，其中变量和A的定义在此提供。本发明还提供了包含这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢紊乱（例如2型糖尿病）的方法。
• BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS
  申请人：Brown Sean P.

  公开号：US20100137323A1

  公开（公告）日：2010-06-03

  The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L 1 , , L 2 ,M, X, L 3 , and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

  本发明提供了一些化合物，例如用于治疗受试者代谢紊乱的化合物。这些化合物具有一般式I，其中变量Q、L1、L2、M、X、L3和A的定义在本文中提供。本发明还提供了包括这些化合物的组合物，以及使用这些化合物制备药物和治疗代谢紊乱的方法，例如II型糖尿病。
• US7687526B2
  申请人：——

  公开号：US7687526B2

  公开（公告）日：2010-03-30
• [EN] BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS<br/>[FR] COMPOSÉS BENZO-FUSIONNÉS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE TROUBLES MÉTABOLIQUES
  申请人：AMGEN INC

  公开号：WO2008030618A1

  公开（公告）日：2008-03-13

  [EN] The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables Q, L¹, ?, L², M, X, L³, and A are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
  [FR] L'invention concerne des composés utilisés notamment dans le traitement de troubles métaboliques chez un individu. Lesdits composés ont la formule générale (1), où la définition des variables Q, L¹, ?, L², M, X, L³, et de A est spécifiée dans la description. L'invention concerne également des compositions et des procédés d'utilisation des composés dans la préparation de médicaments et dans le traitement de troubles métaboliques, tels que le diabète de type II.
• AMP Deaminase Inhibitors. 5. Design, Synthesis, and SAR of a Highly Potent Inhibitor Series
  作者：Srinivas Rao Kasibhatla、Brett C. Bookser、Wei Xiao、Mark D. Erion

  DOI：10.1021/jm000355t

  日期：2001.2.1

  A highly potent AMP deaminase (AMPDA) inhibitor series was discovered by replacing the N3 substitutents of the two lead AMPDA inhibitor series with a conformationally restricted group. The most potent compound, 3-[2-(3-carboxy-4-bromo-5,6,7,8-tetrahydroaphthyl)ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (24b), represents a 10- to 250-fold enhancement in AMPDA inhibitory potency without loss in the enzyme specificity. The potency of the inhibitor 24b (AMPDA K-i = 0.002 muM) is 10(5)-fold lower than the K-m for the substrate AMP. It represents the most potent nonnucleotide AMPDA inhibitor known.